ResMed Inc. (RMD) Shares Bought by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. grew its position in ResMed Inc. (NYSE:RMD) by 3.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 254,561 shares of the medical equipment provider’s stock after buying an additional 8,695 shares during the quarter. Asset Management One Co. Ltd. owned 0.18% of ResMed worth $19,554,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in RMD. FMR LLC increased its position in shares of ResMed by 38.2% in the second quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after buying an additional 1,531,772 shares in the last quarter. Koch Industries Inc. increased its position in shares of ResMed by 17,065.2% in the second quarter. Koch Industries Inc. now owns 985,796 shares of the medical equipment provider’s stock valued at $973,000 after buying an additional 980,053 shares in the last quarter. BlackRock Inc. increased its position in shares of ResMed by 6.8% in the second quarter. BlackRock Inc. now owns 14,240,077 shares of the medical equipment provider’s stock valued at $1,108,877,000 after buying an additional 904,939 shares in the last quarter. Vanguard Group Inc. increased its position in shares of ResMed by 3.3% in the second quarter. Vanguard Group Inc. now owns 11,914,671 shares of the medical equipment provider’s stock valued at $927,797,000 after buying an additional 378,964 shares in the last quarter. Finally, First Trust Advisors LP increased its position in shares of ResMed by 191.8% in the second quarter. First Trust Advisors LP now owns 350,012 shares of the medical equipment provider’s stock valued at $27,255,000 after buying an additional 230,056 shares in the last quarter. Institutional investors and hedge funds own 62.02% of the company’s stock.

ResMed Inc. (NYSE:RMD) traded down $0.60 during trading on Wednesday, reaching $85.84. The company had a trading volume of 493,200 shares, compared to its average volume of 846,984. The stock has a market cap of $12,266.17, a PE ratio of 30.12, a PEG ratio of 1.90 and a beta of 0.78. ResMed Inc. has a 1 year low of $60.13 and a 1 year high of $87.81. The company has a current ratio of 4.72, a quick ratio of 3.86 and a debt-to-equity ratio of 0.50.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting analysts’ consensus estimates of $0.66. The firm had revenue of $523.66 million during the quarter, compared to analysts’ expectations of $506.08 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.62 EPS. equities research analysts predict that ResMed Inc. will post 3.03 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be issued a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.63%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is 56.68%.

A number of analysts recently commented on the company. Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research report on Friday, September 8th. Barclays lifted their price objective on ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a research report on Monday, September 25th. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Jefferies Group reiterated a “sell” rating and set a $56.00 price objective on shares of ResMed in a research report on Thursday, October 12th. Finally, Northland Securities reiterated a “sell” rating and set a $55.00 price objective on shares of ResMed in a research report on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $68.71.

In other ResMed news, insider David Pendarvis sold 6,364 shares of ResMed stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $76.94, for a total value of $489,646.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of ResMed stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $77.01, for a total value of $1,540,200.00. The disclosure for this sale can be found here. Insiders sold a total of 184,693 shares of company stock valued at $15,149,955 in the last 90 days. 1.77% of the stock is owned by company insiders.

WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/13/resmed-inc-rmd-shares-bought-by-asset-management-one-co-ltd.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit